@prefix this: <http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk> .
@prefix sub: <http://purl.org/np/RAj1OdBZEz32H3hM13nGcYskdUTZavqhGSQT_EBPMcUQk#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   <http://purl.obolibrary.org/obo/DOID_5844> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_5844> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00934> ;
    a rdf:Statement ;
    rdfs:label "Maprotiline hydrochloride tablets are contraindicated in patients hypersensitive to maprotiline and in patients with known or suspected seizure disorders. It should not be given concomitantly with monoamine oxidase (MAO) inhibitors. A minimum of 14 days should be allowed to elapse after discontinuation of MAO inhibitors before treatment with maprotiline is initiated. Effects should be monitored with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute phase of myocardial infarction." ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:MedicalContraindication .
  <https://identifiers.org/drugbank:DB00934> bl:category bl:Drug .
}
sub:provenance {
   sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
   sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "dhZfRc575bxoQOZR46xb/A1hQM30wLNF885Gm4fvlaKxveGcWkp+GLZY8t9crRv8EWNNVxnevOI2+8hO/puL8insACSBw3USa8YrpMSJlMf44+hIaeP0mpXQ8SfkSeAKfDK1jS3U15hzJaULewrVDSf/m71SP1Dy9j0AE/6gSBs=" ;
    npx:hasSignatureTarget this: .
  this: dct:created "2021-08-25T14:13:30.145+02:00"^^xsd:dateTime ;
    dct:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}